The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2022
Filed:
Oct. 05, 2017
Applicant:
Baylor College of Medicine, Houston, TX (US);
Inventors:
B. Venkataram Prasad, Houston, TX (US);
Mary K. Estes, Houston, TX (US);
Yongcheng Song, Pearland, TX (US);
Assignee:
Baylor College of Medicine, Houston, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/06 (2006.01); A61K 31/27 (2006.01); A61K 31/40 (2006.01); A61K 31/407 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); G16C 20/50 (2019.01); G16B 15/30 (2019.01); A01N 47/12 (2006.01); C07K 5/068 (2006.01); C07K 5/062 (2006.01); C07D 295/10 (2006.01); A01N 47/28 (2006.01); A01N 47/34 (2006.01); C07C 201/00 (2006.01); C07C 271/18 (2006.01); C07D 498/08 (2006.01); A61K 9/00 (2006.01); A01N 43/90 (2006.01); C07C 271/22 (2006.01); A61K 31/395 (2006.01); A01N 43/64 (2006.01); A01N 37/46 (2006.01);
U.S. Cl.
CPC ...
A61K 38/06 (2013.01); A01N 37/46 (2013.01); A01N 43/64 (2013.01); A01N 43/90 (2013.01); A01N 47/12 (2013.01); A01N 47/28 (2013.01); A01N 47/34 (2013.01); A61K 9/0014 (2013.01); A61K 31/27 (2013.01); A61K 31/395 (2013.01); A61K 31/40 (2013.01); A61K 31/407 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07C 201/00 (2013.01); C07C 271/18 (2013.01); C07C 271/22 (2013.01); C07D 295/10 (2013.01); C07D 498/08 (2013.01); C07K 5/06017 (2013.01); C07K 5/06026 (2013.01); C07K 5/06052 (2013.01); C07K 5/06086 (2013.01); G16B 15/30 (2019.02); G16C 20/50 (2019.02);
Abstract
The present disclosure concerns inhibitors of Norovirus protease that are suitable for use against any genotype of Norovirus, including at least GII.4 Norovirus proteases. In particular embodiments, specific compositions are encompassed, including their use for prevention or treatment of Norovirus infection in an individual.